LGND Form 144: Proposed sale lists 13,423 shares

LGND reported a proposed sale of common stock on a Form 144 with transactions dated 03/04/2026.

Rhea-AI Filing Summary

LGND reported a proposed sale of common stock on a Form 144 with transactions dated 03/04/2026. The filing lists an $2,741,513.52 figure and the number 19,941,141 in the header. The excerpt shows planned sales tied to an exercise of stock options of 2,073 shares on 03/04/2026 and Restricted & Performance Stock Units of 11,350 shares with an award date of 12/31/2025. The sales are shown as common stock to be sold through Morgan Stanley Smith Barney LLC.

Insights

Equity Capital Markets Analyst

Routine Form 144 lists planned insider resale quantities and an aggregate value.

The filing lists a proposed sale of common stock via broker-dealer Morgan Stanley Smith Barney LLC with an aggregate figure of $2,741,513.52 and header number 19,941,141. Specific instruments include an exercise of stock options for 2,073 shares (dated 03/04/2026) and 11,350 restricted and performance stock units (dated 12/31/2025).

Timing and exact proceeds recipients are limited to the excerpt; execution mechanics and final sold amounts depend on broker and holder decisions. Subsequent filings or transaction reports will show completed sale quantities and proceeds.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does LGND's Form 144 dated 03/04/2026 report?

The form reports a proposed sale of common stock with transactions dated 03/04/2026. It shows an aggregate figure of $2,741,513.52 and lists specific lots of 2,073 and 11,350 shares tied to options and RSUs.

Who is handling the proposed LGND stock sales?

The excerpt lists Morgan Stanley Smith Barney LLC as the broker-dealer handling the transactions. The filing identifies sales of common stock through that firm with transaction dates in the excerpt.

How many shares from option exercise and RSUs are included in LGND's filing?

The filing shows an exercise of stock options for 2,073 shares (dated 03/04/2026) and 11,350 restricted & performance stock units (dated 12/31/2025), as listed in the excerpt.

Does LGND's Form 144 show final sale proceeds received by the company?

No final proceeds recipient is specified in the excerpt. The form lists an aggregate figure of $2,741,513.52, but the excerpt does not state whether proceeds go to the issuer or selling holders.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/04/2026 - 04:39 PM EST Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001905248
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	LIGAND PHARMACEUTICALS INCORPORATED
SEC File Number	001-33093
Address of Issuer	555 Heritage Drive, Suite 200 Jupiter FLORIDA 33458
Phone	858-550-7500
Name of Person for Whose Account the Securities are To Be Sold	OCTAVIO ESPINOZA
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	13423	2741513.52	19941141	03/04/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	03/04/2026	Exercise of Stock Options	Issuer			2073	03/04/2026	Cash
Common	12/31/2025	Restricted & Performance Stock Units	Issuer			11350	12/31/2025	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	The securities to be sold were acquired upon the vesting of restricted stock units and performance stock units during the period of 12/31/2025 through 02/15/2026.
Date of Notice	03/04/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	11/19/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Octavio Espinoza
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)